Breast cancer drug Kadcyla price reduction urged
23 April 2014 Last updated at 18:43 BST
The medicines watchdog for England and Wales says it is disappointed that the drug company Roche will not reduce the price of a new breast cancer drug for the NHS.
NICE says the drug, Kadcyla, is too expensive at more than £90,000 a year per patient. The drug can add months to the life of women dying of breast cancer.
Dominic Hughes reports.